



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Service
Prior Authorization Criteria

XIFAXAN® (rifaximin)
[Prior Authorization Request Form](#)

Xifaxan® (rifaximin) is a rifamycin antibacterial indicated for:

- I) Treatment of travelers' diarrhea (TD) caused by noninvasive strains of *Escherichia coli* in adult and pediatric patients 12 years of age and older.
- II) Reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.
- III) Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

Indication –specific Criteria for Approval

- I) **Traveler's diarrhea** (caused by non-invasive strains of *Escherichia coli*)
 1. Request must be for Xifaxan 200 mg tablets; **AND**
 2. Patient must be between twelve (12) and eighteen (18) years of age; **OR**
 3. Patients over eighteen (18) years of age must have had a previous trial of ciprofloxacin.

- II) **Hepatic encephalopathy**
 1. Request must be for Xifaxan 550 mg tablets; **AND**
 2. Patient must be eighteen (18) years of age or older; **AND**
 3. History of treatment with lactulose. *If lactulose has been discontinued, documentation must be included indicating lack of efficacy or the occurrence of an adverse effect.*

- III) **Irritable bowel syndrome with diarrhea (IBS-D)**
 - 1) Request must be for Xifaxan 550 mg tablets; **AND**
 - 2) Patient must be eighteen (18) years of age or older; **AND**
 - 3) History of failure, contraindication or intolerance to **one** of the following:
 - a. Antispasmodic (for example: dicyclomine, hyoscyamine)
 - b. Tricyclic antidepressant (for example: amitriptyline)

All other requests will be approved on a case-by-case basis.



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



References

- 1) Lexi-Comp Clinical Application 05/24/2019
- 2) UpToDate article: Treatment of Irritable Bowel Syndrome in Adults (updated May 23,2019)
- 3) Xifaxan package insert (Rev 5-2015)
- 4) American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. *Am J Gastroenterol* 2014; 109:S2 – S26; doi: 10.1038/ajg.2014.187. (http://gi.org/wp-content/uploads/2014/08/IBS_CIC_Monograph_AJG_Aug_2014.pdf)
- 5) *Am Fam Physician*. 2009 Jun 15;79(12):1108-1117.
<http://www.aafp.org/afp/2009/0615/p1108.html>
- 6) http://www.cdc.gov/Ncidod/dbmd/diseaseinfo/travelersdiarrhea_g.htm
- 7) http://www.aasld.org/sites/default/files/guideline_documents/hepaticencephenhanced.pdf
- 8) <http://pharmpractice.ku.edu/journal-club-digest/rifaximin-use-treatment-hepatic-encephalopathy>
- 9) Rifaximin treatment in hepatic encephalopathy. *N Engl J Med*. 2010 Mar 25;362(12):1071-81
- 10) <https://www.gastro.org/guidelines/ibd-and-bowel-disorders/pharmacological-management-of-irritable-bowel-syndrome-guideline-patient-companion>